

## Supplementary Material

### Quality of Life and Healthcare Resource Use in a Real-world Patient Population with Idiopathic Pulmonary Fibrosis: the PROOF Registry

Wim A. Wuyts<sup>1</sup>, Caroline Dahlqvist<sup>2</sup>, Hans Slabbynck<sup>3</sup>, Marc Schlessler<sup>4</sup>, Natacha Gusbin<sup>5</sup>, Christophe Compere<sup>6</sup>, Sofie Maddens<sup>7</sup>, Shemra Rizzo<sup>8</sup>, Klaus-Uwe Kirchgaessler<sup>9</sup>, Karen Bartley<sup>8</sup> and Benjamin Bondue<sup>10</sup>

<sup>1</sup>Department of Respiratory Medicine, Unit for Interstitial Lung Diseases, University Hospitals Leuven, Leuven, Belgium. E-mail: [wim.wuyts@uzleuven.be](mailto:wim.wuyts@uzleuven.be), <sup>2</sup>CHU UCL Namur Site Godinne, Yvoir, Belgium, E-mail: [caroline.dahlqvist@uclouvain.be](mailto:caroline.dahlqvist@uclouvain.be), <sup>3</sup>Department of Respiratory Medicine, ZNA Middelheim, Antwerp, Belgium. E-mail: [hans.slabbynck@zna.be](mailto:hans.slabbynck@zna.be), <sup>4</sup>Department of Respiratory Care, Hôpitaux Robert Schuman, Luxembourg City, Luxembourg. E-mail: [schlessler.m@pneumo-glacis.lu](mailto:schlessler.m@pneumo-glacis.lu), <sup>5</sup>CHR de la Citadelle, Liège, Belgium. E-mail: [natacha.gusbin@chrcitadelle.be](mailto:natacha.gusbin@chrcitadelle.be), <sup>6</sup>CHIREC Hospital, Brussels, Belgium. Email: [christophe.compere@gmail.com](mailto:christophe.compere@gmail.com), <sup>7</sup>AZ Groeninge, Kortrijk, Belgium. E-mail: [sofie.maddens@azgroeninge.be](mailto:sofie.maddens@azgroeninge.be), <sup>8</sup>Genentech, Inc., South San Francisco, CA, USA. E-mail: [rizzo.shemra@gene.com](mailto:rizzo.shemra@gene.com) and [kbartley15@gmail.com](mailto:kbartley15@gmail.com), <sup>9</sup>F. Hoffmann-La Roche, Ltd., Basel, Switzerland. E-mail: [klaus-uwe.kirchgaessler@roche.com](mailto:klaus-uwe.kirchgaessler@roche.com), <sup>10</sup>Department of Respiratory Medicine, Erasme University Hospital, Brussels, Belgium. E-mail: [benjamin.bondue@erasme.ulb.ac.be](mailto:benjamin.bondue@erasme.ulb.ac.be)

**Correspondence:** Professor Wim A. Wuyts, Department of Respiratory Medicine, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium. E-mail: [wim.wuyts@uzleuven.be](mailto:wim.wuyts@uzleuven.be)

**Table S1** Patient demographics and characteristics at registry inclusion

Parameter <sup>a</sup>	All patients ( <i>N</i> = 277)	Patients ever treated with pirfenidone <sup>b</sup>	
		Yes ( <i>n</i> = 233)	No ( <i>n</i> = 44)
Male	213 (76.9)	181 (77.7)	32 (72.7)
White	255 (92.1)	219 (94.0)	36 (81.8)
Age, years, mean (SD)	69.6 (8.6)	69.4 (8.5)	70.6 (8.9)
Smoking status			
Never	74 (26.7)	65 (27.9)	9 (20.5)
Current	18 (6.5)	15 (6.4)	3 (6.8)
Former	185 (66.8)	153 (65.7)	32 (72.7)
Incidence of comorbidities, mean (SD)	2.5 (1.8)	2.5 (1.8)	3.1 (1.8)
Time since diagnosis to end of enrolment, days, mean (SD)	1284.1 (921.3)	1294.5 (844.8)	1228.7 (1262.5)
Previous treatment for IPF other than pirfenidone			
Nintedanib	9 (3.3)	4 (1.7)	5 (11.4)
N-acetylcysteine	68 (24.6)	62 (26.6)	6 (13.6)
Corticosteroids	50 (18.1)	46 (19.7)	4 (9.1)
Azathioprine	3 (1.1)	2 (0.9)	1 (2.3)
Ambrisentan	1 (0.4)	0 (0)	1 (2.3)
Percent predicted FVC, mean (SD)	80.6 (19.9)	81.2 (19.0)	75.8 (26.2)
Percent predicted DLco, mean (SD)	46.9 (13.8)	47.0 (13.2)	46.0 (18.7)
Supplemental oxygen use	67 (24.2)	61 (26.2)	6 (13.6)

*DLco* diffusing capacity of the lungs for carbon monoxide, *FVC* forced vital capacity, *IPF* idiopathic pulmonary fibrosis, *SD* standard deviation

<sup>a</sup>Data presented as *n* (%) unless otherwise stated

<sup>b</sup>Patients treated with pirfenidone at any time during follow-up in the registry (at the time of registry inclusion or after registry inclusion), for any duration of treatment

**Table S2** Univariate and multivariate associations of QoL at baseline with mortality without multiple imputation

QoL measure	Univariate analyses <sup>a</sup>				Multivariate analyses <sup>a, b</sup>			
	<i>n</i>	HR	95% CI	<i>p</i> -value	<i>n</i>	HR	95% CI	<i>p</i> -value
Cough VAS	272	1.02	(0.97–1.07)	0.4740	215	1.01	(0.96–1.07)	0.7239
EQ-5D VAS score	262	0.90	(0.84–0.96)	0.0008	219	0.93	(0.85–1.02)	0.1402
SGRQ total score	208	1.17	(1.08–1.27)	0.0001	163	1.11	(1.00–1.23)	0.0428
SGRQ impact score	208	1.10	(1.03–1.18)	0.0035	163	1.10	(1.00–1.20)	0.0446
SGRQ activity score	208	1.12	(1.04–1.20)	0.0027	163	1.06	(0.97–1.16)	0.1727
SGRQ symptoms score	208	1.14	(1.06–1.22)	0.0002	163	1.07	(0.99–1.15)	0.1113

*CI* confidence interval, *DLco* diffusing capacity of the lungs for carbon monoxide, *EQ-5D* EuroQoL-5 dimensions Health Questionnaire, *FVC* forced vital capacity, *HR* hazard ratio, *QoL* quality of life, *SGRQ* St. George's Respiratory Questionnaire, *VAS* visual analogue scale

<sup>a</sup>Data were considered missing at random and were not imputed

<sup>b</sup>Multivariate analyses adjusted for age, sex, percent predicted FVC, percent predicted DLco, smoking status and supplementary oxygen use

**Table S3** Outpatient consultations in all patients enrolled in the PROOF registry during the 24-month follow-up period<sup>a</sup>

All patients (N = 277)		
Total number of outpatient consultations	3514	
	<i>n</i>	%
<i>Type of provider</i>		
General practitioner	1513	43.1
Other medical specialist	858	24.4
Pulmonologist	763	21.7
Nurse	254	7.2
Other	125	3.6
Missing	1	0
<i>Site of care</i>		
Caregiver's office/outpatient department	3064	87.2
Patient's home	268	7.6
Patient was hospitalised	182	5.2
<i>Related to</i>		
IPF	2876	81.8
Known comorbidity	143	4.1
New event	131	3.7
IPF treatment ADR	19	0.5
Other	345	9.8

*ADR* adverse drug reaction, *IPF* idiopathic pulmonary fibrosis

<sup>a</sup>Data were considered missing at random and were not imputed

**Table S4** Incidence of hospitalisations in all patients enrolled in the PROOF registry during the 24-month follow-up period<sup>a</sup>

	Month					
	All		Non-respiratory hospitalisation		Respiratory-related hospitalisation	
Total number of hospitalisations	182		61		121	
	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%
<i>Type of provider</i>						
Pulmonologist	98	53.9	0	0	98	81.0
Other medical specialist	73	40.1	57	93.4	16	13.2
General practitioner	1	0.6	1	1.6	0	0
Nurse	0	0	0	0	0	0
Other	10	5.5	3	4.9	7	5.8
<i>Related to</i>						
IPF	95	52.2	0	0	95	78.5
New event	37	20.3	26	42.6	11	9.1
Known comorbidity	13	7.1	9	14.8	4	3.3
IPF treatment ADR	3	1.7	1	1.6	2	1.7
Other	34	18.7	25	41.0	9	7.4
<i>Number of days hospitalised</i>						
<i>N</i>	175		57		118	
Mean (SD)	7.4 (9.2)		7.2 (9.6)		7.5 (9.1)	
Median (IQR)	5 (3–8)		4 (2–8)		5 (3–8)	
Sum	1288		409		879	

*ADR* adverse drug reaction, *IPF* idiopathic pulmonary fibrosis, *IQR* interquartile range, *SD* standard deviation

<sup>a</sup>Data were considered missing at random and were not imputed